Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck sales and marketing update

MRK will withdraw its Vioxx rofecoxib COX-2 inhibitor from markets worldwide. The decision relates

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE